Cathepsin C inhibitors as anti-inflammatory drug discovery: Challenges and opportunities.
Eur J Med Chem
; 225: 113818, 2021 Dec 05.
Article
in English
| MEDLINE | ID: covidwho-1385491
ABSTRACT
Cathepsin C, an important lysosomal cysteine protease, mediates the maturation process of neutrophil serine proteases, and participates in the inflammation and immune regulation process associated with polymorphonuclear neutrophils. Therefore, cathepsin C is considered to be an attractive target for treating inflammatory diseases. With INS1007 (trade name brensocatib) being granted a breakthrough drug designation by FDA for the treatment of Adult Non-cystic Fibrosis Bronchiectasis and Coronavirus Disease 2019, the development of cathepsin C inhibitor will attract attentions from medicinal chemists in the future soon. Here, we summarized the research results of cathepsin C as a therapeutic target, focusing on the development of cathepsin C inhibitor, and provided guidance and reference opinions for the upcoming development boom of cathepsin C inhibitor.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Protease Inhibitors
/
Cathepsin C
/
Drug Discovery
/
Anti-Inflammatory Agents
Limits:
Humans
Language:
English
Journal:
Eur J Med Chem
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS